Lead Sponsor

Lisata Therapeutics, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Men or women age ≥18
•History of and currently experiencing angina at least 3 times per week
•Prior diagnosis of CMD based on coronary flow reserve (CFR) ≤ 2.5 or other measures
•Canadian Cardiovascular Society (CCS) class II, III or IV chronic refractory angina
•No obstructive coronary artery disease
•On stable medical therapy for at least 30 days prior to enrollment
•Must agree to use a reliable and acceptable method of contraception for the duration of participation
•Written informed consent

•Myocardial infarction within 90 days
•Prior evidence of obstructive heart disease including PCI or CABG (or planned PCI or CABG)
•Diagnosis of other specific cardiac disease
•Must meet LVEF and GFR requirements
•Current use of coumadin or DOACs
•Hypersensitivity to GCSF, apheresis or study product components
•Positive for HIV, hepatitis B or hepatitis C
•Active inflammatory or autoimmune disease, or chronic immunosuppressive state
•Drug abuse
•Pregnant or lactating
•Malignant neoplasm within 5 years
•History of Sickle Cell Disease
•Participation in another clinical study within 90 days prior to informed consent or concurrently with this study
•Previous treatment with a CD34+ cell based therapy

Related studies

NCT07093528 · Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction

NCT06991322 · Coronary Microvascular Dysfunction, Coronary Microvascular Disease

NCT05743140 · Coronary Microvascular Disease

NCT05984537 · Coronary Microvascular Dysfunction

NCT06795035 · ST Elevation Myocardial Infarction, Coronary Microvascular Dysfunction, and more

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction